AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. For more information, please select a product below.

DSUVIA™ (in US)
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA Filed
  • Approved
DZUVEO™ (in EU)
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • MAA Filed
  • Approved
Zalviso® (in US)
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • NDA Filed
  • Approved
Zalviso® (in EU)
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • MAA Filed
  • Approved

 

DSUVIA (sufentanil) sublingual tablet 30 mcg

In November of 2018, DSUVIA was approved by the U.S. Food and Drug Administration.

To learn more about DSUVIA, please visit DSUVIA.com.

In June of 2018, AcelRx received approval for DZUVEO from the European Commission for use in medically monitored settings.

Zalviso (sufentanil sublingual tablet system)

Zalviso has completed three Phase 3 clinical trials: two placebo-controlled efficacy and safety trials and one open-label active comparator trial, in which Zalviso was compared to IV PCA morphine. Each of the three Phase 3 trials successfully achieved its primary endpoint. Based on FDA feedback, AcelRx has completed a fourth study (IAP312) in a diverse post-surgical population to further evaluate the overall performance of the Zalviso System.